Kener Laboratories

What Kener Laboratories does

Kener Laboratories (Laboratorios Kener, S.A. de C.V.) is a Mexico-based pharmaceutical company founded in 1960 that develops, manufactures, markets, and distributes generic drugs—including prescription products, OTC medications, medical devices, and cosmetics—with a specialty focus on sterile medications for hospital use. The company's core portfolio spans three product categories: injectables (sterile vials, ampules, and lyophilized products), oral solids (hard gelatin capsules and tablets, including cephalosporins), and ophthalmic solutions. These are organized across twelve therapeutic specialties covering analgesia, anesthesiology, anti-infectives, antifungals, antivirals, cardiovascular, gastroenterology, hematology, immunology, ophthalmology, oncology, and central nervous system conditions.

The company operates a state-of-the-art manufacturing plant in Toluca, State of Mexico, with production areas that have been progressively renewed, including new-generation injectable facilities in 2020, dedicated injectable and ophthalmic manufacturing in 2022, and a further capacity expansion underway in 2025. The company holds related manufacturing IP through its 1989 acquisition of Precimex, a pioneer in Mexican injectables, and operates under strict national and international pharmaceutical standards. Manufacturing capabilities support both captive production for Kener-branded products and third-party contract manufacturing (maquila) for other pharmaceutical companies.

Kener's business model centers on B2B institutional sales to hospitals, pharmacy chains, and government health agencies in Mexico, with direct corporate sales teams managing institutional relationships and dedicated channels for pharmacovigilance and new business development. Revenue is diversified across direct pharmaceutical product sales, contract manufacturing services, and in/out licensing arrangements. Since 2024, Kener has operated as a subsidiary of Grupo Vazol, a diversified conglomerate, while maintaining its own brand and operational identity. The company cites 65+ years of continuous operation, preference among Mexico's most recognized physicians, and efficient supply chain planning as its principal commercial differentiators.

Name

Kener Laboratories

Legal name

Laboratorios Kener, S.A. de C.V.

Website

https://kener.com.mx

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

101–250 employees

Short description

Kener Laboratories is a Mexican pharmaceutical company, founded in 1960, that develops, manufactures, and distributes generic sterile hospital-use injectables, oral solids, and ophthalmics. It serves public health institutions (IMSS, ISSSTE) and private hospitals and pharmacies across Mexico, and is a subsidiary of Grupo Vazol since 2024.

Ownership category

akta.pro rank

Product category

Sterile Hospital Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Sterile injectable manufacturing
• Hospital pharmaceuticals
• Contract manufacturing
• Generic medications
• Pharmaceutical licensing

Headquarters

HQ city

Ciudad De León

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Kener generates primary revenue through the manufacture and sale of sterile hospital-use medications. The company sells directly to hospitals, pharmacy chains, and government health agencies across Mexico, serving both the public and private healthcare sectors.
2. Contract Manufacturing (Maquila): Kener offers contract manufacturing services (maquila) for pharmaceutical products including injectables (vials and ampules, lyophilized), oral solids (hard gelatin capsules, tablets), and ophthalmic solutions. This represents a growth driver for the company.
3. Licensing Agreements (In/Out): Kener engages in In/Out licensing arrangements, incorporating worldwide-quality products and offering reliable solutions that strengthen partner companies. This includes representation of synergistic pharmaceutical companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Kener Laboratories develops, manufactures, and distributes generic pharmaceutical products focused on sterile hospital-use medications, including injectables (vials, ampules, and lyophilized products), oral solids (capsules and tablets), and ophthalmic solutions. Beyond its own branded portfolio, the company offers contract manufacturing (maquila), new product development, in/out licensing, and co-marketing services to other pharmaceutical firms operating in the Mexican hospital segment.

Product overview

Kener Laboratories is a Mexican pharmaceutical company and leader in sterile hospital-use medications. The company operates as a single unified product portfolio organized around three main product types: Injectables (vials, ampules, and lyophilized), Oral Solids (hard gelatin capsules and tablets), and Ophthalmics (solutions). The portfolio is further organized across 12 therapeutic specialties including Analgesia, Anestesia, Antiinfecciosos, Antimicótico, Antivirales, Cardiovascular, Gastroenterología, Hematopoyético, Inmunológicos, Oftalmología, Oncología, and Sistema Nervioso Central. Beyond manufacturing and product development, Kener offers contract manufacturing services (Maquila), co-marketing strategies, and in/out licensing partnerships. The company also provides pharmacovigilance services for adverse reaction reporting. With over 65 years of operation, Kener supplies both public healthcare institutions (IMSS, ISSSTE) and private hospitals and pharmacies across Mexico.

Differentiator

Problem solved

Functional benefit

Brands

• Maquila de productos: Pharmaceutical maquila services including injectables (vials, ampules, and lyophilized), solid oral forms (hard gelatin capsules, tablets), and ophthalmic solutions

Products and services

• Inyectables (Sterile Injectables)

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered growth.

• Pharmaceutical Companies (Contract Manufacturing Partners)growthStrategic or Co-development PartnerKener offers maquila (contract manufacturing) services to other pharmaceutical companies, producing injectables (vials, ampules, lyophilized), oral solids (capsules, tablets), and ophthalmic solutions. This partnership model supports growth and leverages manufacturing capabilities.
• Licensing Partners (In/Out)growthStrategic or Co-development PartnerKener engages in In/Out licensing strategies, incorporating worldwide-quality products and offering reliable pharmaceutical solutions that strengthen partner companies. The company also represents synergistic pharmaceutical companies in the hospital segment.
• Co-marketing PartnersgrowthGTM or Marketing PartnerKener implements co-marketing strategies with pharmaceutical partners to expand market presence and leverage combined portfolios in the hospital medication market.

Scale indicators3 records

Recent moves15 records

Expansion highlights5 records

Regional players

• Genomma Lab Internacional: Large Mexican pharmaceutical company primarily focused on OTC and consumer health, with some institutional presence — broader portfolio than Kener but overlapping Mexican market dynamics and distribution channels.
• Eurofarma Laboratórios: Major Latin American pharmaceutical manufacturer with strong sterile injectable and hospital generics operations across the region — relevant comparable for Kener's specialty injectable strategy and CDMO ambitions.

Direct peers

• Laboratorios Silanes: Established Mexican pharmaceutical company with strong presence in hospital injectables, cardiovascular, and CNS therapeutic areas — directly competes with Kener in sterile hospital medications.
• Laboratorios Liomont: Mexican pharmaceutical manufacturer with broad sterile injectable and oral solid offerings supplied to public and private healthcare channels — overlapping portfolio and customer segments with Kener.
• Laboratorios Sanfer: Mexican pharmaceutical manufacturer focused on specialty therapeutics including sterile injectables and hospital products, serving both public institutions and private healthcare providers.
• Laboratorios Cryopharma: Mexican sterile injectable manufacturer (a Grifols partner) specializing in plasma-derived and injectable hospital products — directly comparable in sterile injectables specialization and institutional customers.
• Laboratorios Pisa: One of Mexico's largest pharmaceutical manufacturers with a strong hospital injectables and sterile generics franchise serving IMSS, ISSSTE, and private hospitals — directly comparable to Kener in product mix, customer base, and go-to-market model.
• Grupo Farmacéutico Somar (Grufesa): Mexican specialty pharma group active in hospital injectables, generics, and institutional supply — comparable in size, product mix, and institutional go-to-market.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with extensive sterile injectable portfolio and growing Latin American footprint — key global incumbent shaping pricing and access in the Mexican hospital injectables market.
• Sandoz (Novartis): Global leader in generic pharmaceuticals and sterile injectables with significant presence in Latin America — sets competitive benchmarks on pricing, scale, and pipeline breadth against which Kener must compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/KenerFarma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kener Laboratories